Posted by Michael Wonder on 19 Apr 2021
ALK gains paediatric approval for its ragweed SLIT tablet in the USA
19 April 2021 - The approval is based on data from one of the largest-ever paediatric SLIT-tablet trials, involving over 1,000 children 5 through 17 years of age in North America and Europe.
ALK today announced that it has gained approval from the US FDA, to expand the use of ALK’s ragweed sublingual allergy immunotherapy (SLIT) tablet Ragwitek (agwizax in Europe) to include paediatric patients, down to the age of 5, with ragweed-induced allergic rhinitis.
